Global Tinea Pedis Treatment Market 2017-2021

  • ID: 4312779
  • Report
  • Region: Global
  • 71 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allergan
  • Bristol-Myers Squibb
  • Galderma
  • Mayne Pharma
  • NanoBio
  • Sanofi
  • MORE
Tinea pedis, also known as athlete’s foot, is caused by dermatophyte fungus on foot and can spread to toenails and hands. It is a dermatophyte infection of the soles of the feet and the interdigital spaces. Tinea pedis thrives in warm, humid conditions and is most common among young adult men. Tinea pedis can be transmitted through direct contact with an infected person or by touching surfaces contaminated with the fungus. This fungus lives in warm, moist environments and is found in showers, locker room floors, and swimming pools.

The report forecasts that the global tinea pedis treatment market to grow at a CAGR of 3.03% during the period 2017-2021.

Covered in this report:

The report covers the present scenario and the growth prospects of the global tinea pedis treatment market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic drugs sales.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
This report, Global Tinea Pedis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion operating in this market.

Key vendors:
  • GSK
  • Exeltis USA
  • Valeant
  • Viamet Pharmaceuticals
Other prominent vendors:
  • Allergan
  • Almirall
  • Amgen
  • Aqua Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Celgene
  • Dermira
  • Elorac
  • F. Hoffmann-La Roche
  • Galderma
  • Genentech
  • Hexima
  • Hisamitsu Pharmaceutical
  • Incyte
  • Mayne Pharma
  • MediQuest Therapeutics
  • Meiji Seika Pharma
  • Merz Pharmaceuticals
  • Moberg Pharma
  • Mylan Pharmaceuticals
  • NanoBio
  • NovaBiotics
  • Novan
  • Nuvo Research
  • Polichem
  • Promius Pharma
  • Sanofi
  • Seren Pharmaceuticals
  • Sun Pharma
  • Taro
  • Teva Pharmaceutical
  • Theravance Biopharma
  • Tinea Pharmaceuticals
Market drivers:
  • High unmet needs
  • For a full, detailed list, view this report
Market challenges:
  • Increased availability of generics and alternative therapies
  • For a full, detailed list, view this report
Market trends:
  • Increased funding for antifungal research
  • For a full, detailed list, view this report
Key questions answered in this report:
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • Bristol-Myers Squibb
  • Galderma
  • Mayne Pharma
  • NanoBio
  • Sanofi
  • MORE
Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction
  • Market outline
Part 05: Pipeline landscape

Part 06: Market landscape
  • Market overview
  • Five forces analysis
Part 07: Market segmentation by ROA
  • Oral
  • Topical
Part 08: Market segmentation by disease type
  • Interdigital tinea pedis
  • Vesicular tinea pedis
Part 09: Geographical segmentation
  • Tinea pedis treatment market in Americas
  • Tinea pedis treatment market in EMEA
  • Tinea pedis treatment market in APAC
Part 10: Decision framework

Part 11: Drivers and challenges
  • Market drivers
  • Market challenges
Part 12: Market trends
  • Increased funding for antifungal research
  • Increased focus on combination therapies
  • Advent of novel therapies
Part 13: Vendor landscape
  • Competitive scenario
Part 14: Key vendor analysis
  • GSK
  • Valeant
  • Exeltis USA
  • Viamet Pharmaceuticals
  • Other prominent vendors
Part 15: Appendix

List of abbreviations

List of Exhibits
Exhibit 01: Symptoms of tinea pedis
Exhibit 02: Pipeline analysis
Exhibit 03: Global tinea pedis treatment market: Snapshot
Exhibit 04: Global tinea pedis treatment market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis: Global tinea pedis treatment market
Exhibit 06: Five forces analysis
Exhibit 07: Global tinea pedis treatment market by ROA 2016
Exhibit 08: Global tinea pedis treatment market by disease type 2016
Exhibit 09: Global interdigital tinea pedis treatment market 2016-2021 ($ millions)
Exhibit 10: Global vesicular tinea pedis treatment market 2016-2021 ($ millions)
Exhibit 11: Global tinea pedis treatment market by geography 2016 and 2021
Exhibit 12: Global tinea pedis treatment market by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: Tinea pedis treatment market in Americas 2016-2021 ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: Tinea pedis treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Market scenario of APAC
Exhibit 18: Tinea pedis treatment market in APAC 2016-2021 ($ millions)
Exhibit 19: Competitive structure analysis of global tinea pedis treatment market 2016
Exhibit 20: Strategic success factors of companies in global tinea pedis treatment market
Exhibit 21: GSK: Strength assessment
Exhibit 22: GSK: Strategy assessment
Exhibit 23: GSK: Opportunity assessment
Exhibit 24: Valeant: Key highlights
Exhibit 25: Valeant: Strength assessment
Exhibit 26: Valeant: Strategy assessment
Exhibit 27: Valeant: Opportunity assessment
Exhibit 28: Exeltis USA: Strength assessment
Exhibit 29: Exeltis USA: Strategy assessment
Exhibit 30: Exeltis USA: Opportunity assessment
Exhibit 31: Viamet Pharmaceuticals: Strength assessment
Exhibit 32: Viamet Pharmaceuticals: Strategy assessment
Exhibit 33: Viamet Pharmaceuticals: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan
  • Bristol-Myers Squibb
  • Galderma
  • Mayne Pharma
  • NanoBio
  • Sanofi
  • MORE
New Research Report - Global Tinea Pedis Treatment Market 2017-2021

Other Prominent Vendors in the market are: Allergan, Almirall, Amgen, Aqua Pharmaceuticals, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dermira, Elorac, F. Hoffmann-La Roche, Galderma, Genentech, Hexima, Hisamitsu Pharmaceutical, Incyte, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharmaceuticals, Moberg Pharma, Mylan Pharmaceuticals, NanoBio , NovaBiotics, Novan , Nuvo Research, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Sun Pharma, Taro, Teva Pharmaceutical, Theravance Biopharma, and Tinea Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is increased funding for antifungal research. The growing cases of infectious diseases such as bacterial infection, fungal infection, and viral infection are encouraging vendors to enhance their R&D efforts in this therapy area. As drug development is a cost-intensive process, funding has always been a concern to vendors. This has led to various government and non-governmental institutes to take part in the development of antifungal drugs by providing the required funding to research institutes and companies.”

According to the report, one of the major drivers for this market is high unmet needs. The global tinea pedis treatment market faces significant unmet needs due to low treatment efficacy and prolonged treatment duration. Certain drugs show their efficacy only in the treatment of mild cases of infection. Also, the infection continues to recur as the treatment does not completely cure it. Multiple cycles of unsuccessful treatments increase patient discomfort. This creates a large gap between the demand for and supply of these therapeutics. Thus, the market provides a growth opportunity for vendors with the increasing demand for effective pharmacological therapeutics for fungal infections.

Further, the report states that one of the major factors hindering the growth of this market is increased availability of generics and alternative therapies. The easy availability of alternative treatments for tinea pedis can hamper the market growth. Alternative medications such as tea tree oil, Himalayan crystal salt, apple cider vinegar, garlic, neem oil, oregano oil are used to treat tinea pedis. Also, the preference for alternative therapies such as homeopathy and laser treatments restricts the market growth. Such instances also decrease the therapeutic share of the tinea pedis treatment market. Apart from this, the availability of generic products such as itraconazole, terbinafine, and fluconazole and the patent expiry of many drugs has led to a further decline in market shares.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • GSK
  • Exeltis USA
  • Valeant
  • Viamet Pharmaceuticals
  • Allergan
  • Almirall
  • Amgen
  • Aqua Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Celgene
  • Dermira
  • Elorac
  • F. Hoffmann-La Roche
  • Galderma
  • Genentech
  • Hexima
  • Hisamitsu Pharmaceutical
  • Incyte
  • Mayne Pharma
  • MediQuest Therapeutics
  • Meiji Seika Pharma
  • Merz Pharmaceuticals
  • Moberg Pharma
  • Mylan Pharmaceuticals
  • NanoBio
  • NovaBiotics
  • Novan
  • Nuvo Research
  • Polichem
  • Promius Pharma
  • Sanofi
  • Seren Pharmaceuticals
  • Sun Pharma
  • Taro
  • Teva Pharmaceutical
  • Theravance Biopharma
  • Tinea Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll